Favorable Drug Pricing Language In COVID-19 Government Contracts May Backfire for Industry

 
• By Sarah Karlin-Smith
NIH Director Francis Collins displays a 3D model of the coronavirus during testimony at a US Senate Appropriations Committee hearing on 2 July 2020.
US NIH Director Francis Collins holds a 3D model of coronavirus during a Senate Appropriations Committee hearing on 2 July. The Pharma industry hopes that Collins’ view of ‘march-in’ rights becomes the model for government and public opinion.

More from Pricing Debate

More from Market Access